Delexcel Pharma Profile
Key Indicators
- Authorised Capital ₹ 16.00 Cr
- Paid Up Capital ₹ 10.00 Cr
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 25.00 Cr
- Revenue Growth 38.33%
- Profit Growth 84.47%
- Ebitda 165.25%
- Net Worth -47.84%
- Total Assets 7.00%
About Delexcel Pharma
Delexcel Pharma Private Limited (DPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 04 September 2014 and has a history of Ten years and five months. Its registered office is in Medak, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 16.00 Cr and a paid-up capital of Rs 10.00 Cr.
The company currently has active open charges totaling ₹25.00 Cr.
The Key Managerial Personnel (KMP) at Delexcel Pharma Private Limited India is Raghupathi Kandarapu as CEO. Madhava Tumati, Venkata Tumati, and Raghupathi Kandarapu serve as directors at the Company.
Company Details
-
Location
Medak, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24232TG2014PTC095535
-
Company No.
095535
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Sep 2014
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Delexcel Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raghupathi Kandarapu
|
CEO | 04-Jun-2016 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Raghupathi Kandarapu
|
Director and Ceo | 04-Jun-2016 | Current |
|
Madhava Tumati
|
Director | 04-Sep-2014 | Current |
|
Venkata Tumati
|
Director | 04-Sep-2014 | Current |
Financial Performance of Delexcel Pharma.
Delexcel Pharma Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 38.33% increase. The company also saw a substantial improvement in profitability, with a 84.47% increase in profit. The company's net worth observed a substantial decline by a decrease of 47.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Delexcel Pharma?
In 2021, Delexcel Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Deccan Abode Private LimitedMadhava Tumati is a mutual person
-
Tmr Developers Private Limited
Madhava Tumati and Venkata Tumati are mutual person
Charges (Loans)
₹25.00 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 25.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Feb 2017 | Others | ₹25.00 Cr | Open |
How Many Employees Work at Delexcel Pharma?
Delexcel Pharma has a workforce of 67 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Delexcel Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Delexcel Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.